In a prespecified secondary analysis of the ASTRUM-005 trial (585 patients, extensive-stage SCLC), serplulimab plus chemotherapy improved median OS vs placebo (15.8 vs 11.1 months; HR 0.60) at median 42.4 months' follow-up; grade ≥3 related AEs 35.0% vs 29.1%.
Secondary analysisn = 585
Liu et al. First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial